Publication | Open Access
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
46
Citations
28
References
2018
Year
Otsuka Pharmaceutical Development and Commercialization, Inc. and Lundbeck.
| Year | Citations | |
|---|---|---|
Page 1
Page 1